Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine added to tamsulosin in benign prostatic hyperplasia with irritative symptoms
IRCT20190928044913N1Phase 3Completed
- Sponsor
- Sabzevar University of Medical Sciences
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolterodine in benign prostatic hyperplasia (BPH), sponsored by Sabzevar University of Medical Sciences. Primary endpoints: uroflowmetry, prostate volume and 1 more. Started Apr 2019; status: completed.
02
Drugs
tolterodine
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on IRCT20190928044913N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190928044913N1.